196 related articles for article (PubMed ID: 17212760)
1. Differential capacities of outer membrane proteins from Neisseria meningitidis B to prime the murine immune system after vaccination.
Silva Junior FC; Gioia CA; Oliveira JM; Cruz SC; Frasch CE; Milagres LG
Scand J Immunol; 2007 Jan; 65(1):1-7. PubMed ID: 17212760
[TBL] [Abstract][Full Text] [Related]
2. Effect of a booster dose of serogroup B meningococcal vaccine on antibody response to Neisseria meningitidis in mice vaccinated with different immunization schedules.
Gioia CA; de Sousa AB; Cruz SC; Junior FC; Andrade AF; Sassi RM; Frasch CE; Milagres LG
FEMS Immunol Med Microbiol; 2005 Apr; 44(1):35-42. PubMed ID: 15780576
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease.
Norheim G; Arne Høiby E; Caugant DA; Namork E; Tangen T; Fritzsønn E; Rosenqvist E
Vaccine; 2004 Jun; 22(17-18):2171-80. PubMed ID: 15149774
[TBL] [Abstract][Full Text] [Related]
4. Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis.
Marzoa J; Sánchez S; Costoya L; Diéguez-Casal E; Freixeiro P; Brookes C; Allen L; Taylor S; Gorringe AR; Ferreirós CM; Criado MT
Vaccine; 2012 Mar; 30(13):2387-95. PubMed ID: 21911024
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.
Keiser PB; Biggs-Cicatelli S; Moran EE; Schmiel DH; Pinto VB; Burden RE; Miller LB; Moon JE; Bowden RA; Cummings JF; Zollinger WD
Vaccine; 2011 Feb; 29(7):1413-20. PubMed ID: 21199704
[TBL] [Abstract][Full Text] [Related]
6. Human antibody and memory B and T-cell responses after primary and booster immunisation against Neisseria meningitidis B.
Cruz SC; Souza SL; Cruz AC; Silva GP; Milagres LG
Vaccine; 2011 Oct; 29(43):7387-94. PubMed ID: 21803107
[TBL] [Abstract][Full Text] [Related]
7. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
[TBL] [Abstract][Full Text] [Related]
8. Comparison of long-term humoral memory development after immunisation against Neisseria meningitidis B or diphtheria toxoid.
Cruz SC; Silva GP; Sampaio FJ; Souza SL; Dias AA; Milagres LG
Vaccine; 2010 Oct; 28(42):6841-6. PubMed ID: 20719254
[TBL] [Abstract][Full Text] [Related]
9. Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.
Matthias KA; Reveille A; Connolly KL; Jerse AE; Gao YS; Bash MC
Vaccine; 2020 Feb; 38(10):2396-2405. PubMed ID: 32037226
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254.
Vipond C; Suker J; Jones C; Tang C; Feavers IM; Wheeler JX
Proteomics; 2006 Jun; 6(11):3400-13. PubMed ID: 16645985
[TBL] [Abstract][Full Text] [Related]
11. Generation of long-lived plasma cells to serogroup B Neisseria meningitidis after murine immunisation with an outer membrane protein vaccine.
Cruz SC; Cruz AC; Oliveira JM; Soares AM; Gioia CA; Milagres LG
Vaccine; 2007 Jun; 25(27):5046-52. PubMed ID: 17524531
[TBL] [Abstract][Full Text] [Related]
12. PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children.
Vermont CL; Van Dijken HH; De Groot R; Van Alphen L; Van Den Dobbelsteen GP
Vaccine; 2004 Aug; 22(23-24):3008-13. PubMed ID: 15297049
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
Snape MD; Dawson T; Oster P; Evans A; John TM; Ohene-Kena B; Findlow J; Yu LM; Borrow R; Ypma E; Toneatto D; Pollard AJ
Pediatr Infect Dis J; 2010 Nov; 29(11):e71-9. PubMed ID: 20844462
[TBL] [Abstract][Full Text] [Related]
14. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
[TBL] [Abstract][Full Text] [Related]
15. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
[TBL] [Abstract][Full Text] [Related]
16. Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies.
Rosenqvist E; Høiby EA; Bjune G; Bryn K; Closs O; Feiring B; Klem A; Nøkleby H; Frølm LO
NIPH Ann; 1991 Dec; 14(2):169-79; discussion 180-1. PubMed ID: 1687481
[TBL] [Abstract][Full Text] [Related]
17. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
Vermont CL; van Dijken HH; van Limpt CJ; de Groot R; van Alphen L; van Den Dobbelsteen GP
Infect Immun; 2002 Feb; 70(2):584-90. PubMed ID: 11796586
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA.
Keiser PB; Gibbs BT; Coster TS; Moran EE; Stoddard MB; Labrie JE; Schmiel DH; Pinto V; Chen P; Zollinger WD
Vaccine; 2010 Oct; 28(43):6970-6. PubMed ID: 20732470
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
